SCHEMBL17456041

SCHEMBL17456041

Fc1ccc(-c2ccncc2)c(OC2CCN(Cc3ccccc3)C2)c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP11B1 P15538 1/20 0.53
▸ CYP11B2 P19099 1/20 0.53
▸ MCHR1 Q99705 2/20 0.51
▸ ROCK1 Q13464 2/20 0.48
▸ ROCK2 O75116 1/20 0.48
▸ SCN8A Q9UQD0 7/20 0.45
▸ SCN1A P35498 3/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ BCHE P06276 3/20 0.43
▸ ACHE P22303 3/20 0.43
▸ BACE1 P56817 3/20 0.43
▸ DRD2 P14416 1/20 0.42
▸ HTR2A P28223 1/20 0.42
▸ HTR2C P28335 1/20 0.42
▸ HTR2B P41595 1/20 0.42
▸ SIGMAR1 Q99720 1/20 0.42
▸ CCNT1 O60563 1/20 0.42
▸ CDK9 P50750 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17455994 0.94 CYP11B1 (0.55) CYP11B1CYP11B2ROCK1ROCK2SCN8A
SCHEMBL17455972 0.93 MCHR1 (0.50) CYP11B1CYP11B2MCHR1ROCK1ROCK2
SCHEMBL17455978 0.87 MCHR1 (0.47) CYP11B1CYP11B2MCHR1ROCK1ROCK2
SCHEMBL17455985 0.86 SMN1; SMN2 (0.50) CYP11B1CYP11B2ROCK1ROCK2SCN8A
SCHEMBL17455938 0.82 SMN1; SMN2 (0.57) MCHR1ROCK1ROCK2SMN1; SMN2BCHE
SCHEMBL17456055 0.81 MCHR1 (0.53) MCHR1SCN8ASCN1ASMN1; SMN2BCHE
SCHEMBL17455920 0.81 CYP46A1 (0.57) ROCK1SCN8ASCN1ASMN1; SMN2ACHE
SCHEMBL17456046 0.81 MCHR1 (0.53) CYP11B1CYP11B2MCHR1ROCK1ROCK2
SCHEMBL17455957 0.77 MCHR1 (0.48) MCHR1SCN8ASCN1ASMN1; SMN2BCHE
SCHEMBL10606002 0.75 HRH3 (0.59) MCHR1ROCK1ROCK2SMN1; SMN2BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024049-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 CYP11B1 88/4885CYP11B2 82/4885MCHR1 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback